Larimar Therapeutics (LRMR) Price to Book (2020 - 2026)

Larimar Therapeutics (LRMR) has reported Price to Book for 7 consecutive years, with 2.49 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 61.11% year-over-year to 2.49; the trailing twelve-month figure through Jun 2026 stood at 2.49 (up 61.11% YoY), and the FY2025 full-year result was 4.05, up 182.05% from the prior year.
• Price to Book slipped to 2.49 in Q2 2026 per LRMR's latest filing, from 4.05 in the prior quarter.
• Across five years, Price to Book topped out at 4.05 in Q4 2025 and bottomed at 0.6 in Q3 2022.
• Historically, Price to Book has averaged 1.76 across 5 years, with a median of 1.84 in 2023.
• The sharpest annual moves came in 2022 and 2023: Price to Book tumbled 78.84% in 2022, then surged 212.06% in 2023.
• Over 5 years, Price to Book stood at 0.96 in 2022, then surged by 154.84% to 2.44 in 2023, then slumped by 41.2% to 1.44 in 2024, then soared by 182.05% to 4.05 in 2025, then sank by 38.65% to 2.49 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 2.49, 4.05, and 1.99 for Q2 2026, Q4 2025, and Q3 2025 respectively.